drugset / Trial / NCT06500689
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Allisartan Isoproxil (240 mg).
Timeline
- Start
- 2021-12-30
- Primary completion
- 2023-11-27
- Completion
- 2024-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allisartan Isoproxil | Unknown | 240 mg | Oral |
| Subject | Indapamide | Small molecule | 1.5 mg | Oral |